Is the Measured Diameter of the Optic Nerve Sheath by Cerebral Scan in Patients With Early-phase Meningeal Hemorrhage, Due to a Ruptured Aneurysm, a Prognostic 6-month Mortality Factor ?
NCT ID: NCT02894034
Last Updated: 2018-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
114 participants
OBSERVATIONAL
2013-08-19
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture
NCT05450939
Predictors of Rupture Risk of Intracranial Aneurysms
NCT04613427
Prediction of Secondary Neurological Deterioration in Patients With Moderate Traumatic Brain Injury
NCT04854954
Early Brain Damage Assessment in Aneurysmal Subarachnoid Haemorrhage in Predicting Cognitive Impairment
NCT06172556
Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies
NCT06781034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prognostic tools are indispensable in guiding and optimizing the care of these patients.
Some diagnostic factors have been identified (e.g. age, comorbidities, ACSOS , GCS, ICP, occurrence of complications) as well as some classification schemes used for grading seriousness of the disease (Hunt and Hess, World Federation of NeuroSurgery).
A tool that is simple, reliable, reproducible, non costly, non invasive, and simple to perform (including remote methods and without changing planned patient care) would be ideal.
The measurement of the Optic Nerve Sheath Diameter (ONSD,) correlated by MRI and ultrasound in previous studies, with intra-cranial pressure (ICP: a fundamental prognostic factor for SAH) could be one of these tools.
This measurement, previously demonstrated using ultrasound, could be carried out at the time of the patient's initial cerebral scan.
In practice, at admission each patient undergoes a cerebral CT scan much more often than an ultrasound (faster, less costly, less technical training required).
Two preliminary studies seem to suggest that this measurement of ONSD on CTc is a predictive factor for morbi-morbidity in patients having serious traumatic skull fractures.The measurement is reliable, reproducible, non invasive, and non costly, with good sensitivity and specificity.
Proving that it is also applicable to SAH could be particularly useful.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient admitted to the Neurosurgical Urgent Care Unit for SAH following a ruptured aneurysm
* Patients or one of their loved ones providing written informed consent
* Patients with healthcare coverage
Exclusion Criteria
* Trauma to the optic globe or optic nerve pathology
* Preexisting anomalies of ICP or history of neurosurgical cerebral pathologies
* SAH of non aneurysm origin (e.g. arterio-venous malformation (AVM), tumor, trauma, sepsis)
* Patients under legal protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire, Amiens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick JEANJEAN, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Amiens
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PI2013_843_0009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.